Key facts
- Deciphex’s last known valuation is $39.4M (Oct 2023).
- It has raised $93.2M; the latest was Debt - General ($15.0M) in Oct 2025.
- Notable investors include Enterprise Ireland, European Union, Molten Ventures, Claret Capital Partners, Act Venture Capital — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Deciphex
- ·The full record, as it builds
Funding rounds
No funding rounds for Deciphex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Deciphex
Developer of medical software applications designed for preclinical pathology. The company's applications use a combination of digital pathology and artificial intelligence to triage out high-volume, low complexity samples and specialize in human gastrointestinal and toxicological pathology use cases, enabling pathologists to focus on critical content and improve productivity.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2017
- Employees
- 220
- Website
- deciphex.com/
- Ownership
- Privately Held (backing)
Deciphex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Deciphex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Deciphex in its N-PORT filings yet. We sweep new filings monthly.